To Compare and Demonstrate the Safety and Efficacy of Antithrombotic Agents and Fibrinolytics in the Management of Acute Coronary Syndrome Assessment, Evaluation and Management of Adverse Events

Antithrombotic therapy and Fibrinolytics are central to the management of Acute Coronary Syndrome. These are high alert medications that are prone to adverse effects thus requiring strict monitoring. Effective usage of these medications results in reduction of recurrent ischaemic events including MI and stent thrombosis. Reducing the ischemic events and maintaining a balance between normal physiological coagulability and the bleeding is vital to avoid bleeding complications during the therapy. This therapy induced adverse effects increases mortality and morbidity rate. In our study we are mainly focussing on, comparing and demonstrating the effectiveness of enoxaparin over heparin and Tenecteplase over streptokinase and to assess, evaluate and management of adverse events by Narinjo assessment scale. Majority of adverse events were seen in subjects with social history of alcoholism, this shows alcoholism decreasing the threshold to adverse events. Causality assessment of adverse effects were 17.45% Possible and 91.6% were probable. The streptokinase was found superior than tenecteplase and enoxaparin was found superior than heparin in terms of adverse events and hospitalisation period. ACS is an drastic health disorder that increases the morbidity rate, mortality rate, economic burden and well being of the persons. Thus individualisation of drug regimen and strategies for early detection, monitoring and management of adverse events is mandatory.